Bredius R G, Driedijk P C, Schouten M F, Weening R S, Out T A
Clinical Immunology Laboratory, Academic Medical Center, Amsterdam, The Netherlands.
Infect Immun. 1992 Nov;60(11):4838-47. doi: 10.1128/iai.60.11.4838-4847.1992.
To obtain information on effector functions of human immunoglobulin G2 (IgG2), we have measured the complement-activating properties of polyclonal IgG subclass antibodies against bacterial antigens. IgG1 and IgG2 were purified from serum samples from five healthy individuals, and complement activation was measured with different bacterial antigens. We used Staphylococcus aureus Wood 46 (STAW), which is a common antigen, Haemophilus influenzae type b (Hib), which is a common pathogenic microorganism in children, and formaldehyde-inactivated tetanus toxin (TT). Bacteria were incubated with antibodies and then incubated with sera from agammaglobulinemic patients as a complement source, and C3c deposition was measured by enzyme-linked immunosorbent assay. We found that anti-STAW IgG2 activated complement to a level similar to that of anti-STAW IgG1. Anti-Hib IgG1 complement activation was as much as seven times higher than that of anti-Hib IgG2 in four individuals. In one individual, anti-Hib IgG2 was more effective in complement activation than anti-Hib IgG1. Anti-TT antibodies showed patterns similar to those of anti-Hib. Our results indicate that IgG2 antibodies may contribute significantly to antibacterial defense. Also, individual differences in antibody effector functions should be taken into account when evaluating the immune status of patients and during early phase 1 studies of new vaccines.
为获取有关人免疫球蛋白G2(IgG2)效应功能的信息,我们测定了多克隆IgG亚类抗体针对细菌抗原的补体激活特性。从五名健康个体的血清样本中纯化出IgG1和IgG2,并使用不同的细菌抗原测定补体激活情况。我们使用了金黄色葡萄球菌伍德46株(STAW,一种常见抗原)、b型流感嗜血杆菌(Hib,儿童常见致病微生物)以及甲醛灭活破伤风毒素(TT)。将细菌与抗体孵育,然后与来自无丙种球蛋白血症患者的血清作为补体来源一起孵育,通过酶联免疫吸附测定法测量C3c沉积。我们发现抗STAW IgG2激活补体的水平与抗STAW IgG1相似。在四名个体中,抗Hib IgG1的补体激活比抗Hib IgG2高出多达七倍。在一名个体中,抗Hib IgG2在补体激活方面比抗Hib IgG1更有效。抗TT抗体表现出与抗Hib抗体相似的模式。我们的结果表明,IgG2抗体可能在抗菌防御中发挥重要作用。此外,在评估患者免疫状态以及新疫苗1期早期研究期间,应考虑抗体效应功能的个体差异。